Ascletis Pharma (HKG:1672) commenced a phase 1 study for the ASC36 oral tablets in the U.S. for the treatment of obesity.
The trial will study the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral amylin receptor peptide agonist in 86 participants with obesity, according to a Tuesday bourse disclosure.